Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer.

Autor: Munkley J; Institute of Genetic Medicine, University of Newcastle, Newcastle, United Kingdom., Li L; Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, United Kingdom., Krishnan SRG; Institute of Genetic Medicine, University of Newcastle, Newcastle, United Kingdom., Hysenaj G; Institute of Genetic Medicine, University of Newcastle, Newcastle, United Kingdom., Scott E; Institute of Genetic Medicine, University of Newcastle, Newcastle, United Kingdom., Dalgliesh C; Institute of Genetic Medicine, University of Newcastle, Newcastle, United Kingdom., Oo HZ; Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.; Vancouver Prostate Centre, Vancouver, Canada., Maia TM; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.; VIB Center for Medical Biotechnology, VIB, Ghent, Belgium.; VIB Proteomics Core, VIB, Ghent, Belgium.; Department for Biomolecular Medicine, Ghent University, Ghent, Belgium., Cheung K; Bioinformatics Support Unit, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom., Ehrmann I; Institute of Genetic Medicine, University of Newcastle, Newcastle, United Kingdom., Livermore KE; Institute of Genetic Medicine, University of Newcastle, Newcastle, United Kingdom., Zielinska H; Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, United Kingdom., Thompson O; Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, United Kingdom., Knight B; NIHR Exeter Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom., McCullagh P; Department of Pathology, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom., McGrath J; Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom., Crundwell M; Department of Urology, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom., Harries LW; Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, United Kingdom., Daugaard M; Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.; Vancouver Prostate Centre, Vancouver, Canada., Cockell S; Bioinformatics Support Unit, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom., Barbosa-Morais NL; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal., Oltean S; Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, United Kingdom., Elliott DJ; Institute of Genetic Medicine, University of Newcastle, Newcastle, United Kingdom.

Publikováno v: ELife [Elife] 2019 Sep 03; Vol. 8. Date of Electronic Publication: 2019 Sep 03.

Androgen-dependent alternative mRNA isoform expression in prostate cancer cells.

Autor: Munkley J; Institute of Genetic Medicine, University of Newcastle, Newcastle upon Tyne, Newcastle, NE1 3BZ, UK., Maia TM; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, 1649-028, Portugal.; VIB Proteomics Core, Albert Baertsoenkaai 3, Ghent, 9000, Belgium., Ibarluzea N; Institute of Genetic Medicine, University of Newcastle, Newcastle upon Tyne, Newcastle, NE1 3BZ, UK.; Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Barakaldo, 48903, Spain.; Centre for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Valencia, 46010, Spain., Livermore KE; Institute of Genetic Medicine, University of Newcastle, Newcastle upon Tyne, Newcastle, NE1 3BZ, UK., Vodak D; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Ehrmann I; Institute of Genetic Medicine, University of Newcastle, Newcastle upon Tyne, Newcastle, NE1 3BZ, UK., James K; Interdisciplinary Computing and Complex BioSystems Research Group, Newcastle University, Newcastle upon Tyne, NE4 5TG, UK.; Life and Earth Sciences, Natural History Museum, Cromwell Road, London, SW7 5BD, UK., Rajan P; Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, EC1M 6BQ, UK., Barbosa-Morais NL; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, 1649-028, Portugal., Elliott DJ; Institute of Genetic Medicine, University of Newcastle, Newcastle upon Tyne, Newcastle, NE1 3BZ, UK.

Publikováno v: F1000Research [F1000Res] 2018 Aug 03; Vol. 7, pp. 1189. Date of Electronic Publication: 2018 Aug 03 (Print Publication: 2018).

The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer.

Autor: Munkley J; Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, UK., Oltean S; Microvascular Research Laboratories, School of Physiology and Pharmacology, University of Bristol, Bristol, UK., Vodák D; Bioinformatics Core Facility, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Wilson BT; Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, UK., Livermore KE; Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, UK., Zhou Y; Beatson Institute for Cancer Research, Glasgow, UK., Star E; Microvascular Research Laboratories, School of Physiology and Pharmacology, University of Bristol, Bristol, UK., Floros VI; Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, UK., Johannessen B; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Knight B; NIHR Exeter Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK., McCullagh P; Department of Pathology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK., McGrath J; Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK., Crundwell M; Department of Urology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK., Skotheim RI; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Robson CN; Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK., Leung HY; Beatson Institute for Cancer Research, Glasgow, UK.; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Harries LW; Institute of Biomedical and Clinical Sciences, University of Exeter, Devon, UK., Rajan P; Beatson Institute for Cancer Research, Glasgow, UK.; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Mills IG; Prostate Cancer Research Group, Centre for Molecular Medicine Norway (NCMM), University of Oslo and Oslo University Hospitals, Oslo, Norway.; Departments of Molecular Oncology, Institute of Cancer Research and Radium Hospital, Oslo, Norway.; PCUK/Movember Centre of Excellence for Prostate Cancer Research, Centre for Cancer Research and Cell Biology (CCRCB), Queen's University, Belfast, UK., Elliott DJ; Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, UK.

Publikováno v: Oncotarget [Oncotarget] 2015 Oct 27; Vol. 6 (33), pp. 34358-74.